id,tipo,text_start,text_end,text
id,tipo,text_start,text_end,text
10735891,Claim,1,136,"Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC)."
10735891,Premise,876,998,"Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001)."
10735891,Premise,999,1113,"Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),"
10735891,Premise,1118,1207,"duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027)."
10735891,Premise,1208,1305,"Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)"
10735891,Premise,1310,1440,"the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin."
10735891,Premise,1441,1523,"Neither quality of life nor performance status was decreased by suramin treatment,"
10735891,Premise,1528,1557,"overall survival was similar."
10735891,Premise,1558,1647,"Most adverse events were of mild or moderate intensity and were easily managed medically."
10735891,Claim,1648,1817,"Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC."
10811675,Premise,1276,1478,"Time to progression was longer for docetaxel patients than for best supportive care patients (10.6 v 6.7 weeks, respectively; P <.001), as was median survival (7.0 v 4.6 months; log-rank test, P =.047)."
10811675,Premise,1479,1701,"The difference was more significant for docetaxel 75 mg/m(2) patients, compared with corresponding best supportive care patients (7.5 v 4.6 months; log-rank test, P =.010; 1-year survival, 37% v 11%; chi(2) test, P =.003)."
10811675,Premise,1702,1855,"Febrile neutropenia occurred in 11 patients treated with docetaxel 100 mg/m(2), three of whom died, and in one patient treated with docetaxel 75 mg/m(2)."
10811675,Premise,1856,2007,"Grade 3 or 4 nonhematologic toxicity, with the exception of diarrhea, occurred at a similar rate in both the docetaxel and best supportive care groups."
10811675,Claim,2008,2089,"Treatment with docetaxel is associated with significant prolongation of survival,"
10811675,Claim,2094,2172,"at a dose of 75 mg/m(2), the benefits of docetaxel therapy outweigh the risks."
11766999,Claim,1,185,"In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability."
11766999,Premise,755,916,"After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale."
11766999,Premise,917,1172,"Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale."
11766999,Claim,1173,1246,"A steady improvement in quality of life was also observed in both groups."
11766999,Premise,1247,1315,"There were no clinically significant differences between the groups."
11766999,Premise,1316,1559,"In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy."
11766999,Premise,1560,1682,"Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%)."
11766999,Claim,1716,1833,"paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer."
11766999,Claim,186,252,"Prompt diagnosis and effective treatment is, therefore, essential."
11786563,Claim,1,190,"In a randomized clinical trial in patients with advanced non-small-cell lung cancer (NSCLC), infusion with adenosine 5'-triphosphate (ATP) inhibited loss of body weight and quality of life."
11786563,Premise,894,1205,"No change in body composition over the 28-week follow-up period was found in the ATP group, whereas, per 4 weeks, the control group lost 0.6 kg of FM (P =.004), 0.5 kg of FFM (P =.02), 1.8% of arm muscle area (P =.02), and 0.6% of BCM/kg body weight (P =.054) and decreased 568 KJ/d in energy intake (P =.0001)."
11786563,Premise,1206,1313,"Appetite also remained stable in the ATP group but decreased significantly in the control group (P =.0004)."
11786563,Premise,1314,1397,"No significant differences in REE between the ATP and control groups were observed."
11786563,Claim,1398,1567,"The inhibition of weight loss by ATP infusions in patients with advanced NSCLC is attributed to counteracting the loss of both metabolically active and inactive tissues."
11786563,Premise,1568,1634,"These effects are partly ascribed to maintenance of energy intake."
11788911,Premise,1598,1765,"At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free."
11788911,Premise,1766,1953,"The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22)."
11788911,Premise,1954,2071,"The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia."
11788911,Claim,2094,2229,"the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed."
11788911,Claim,2245,2371,"this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;"
11788911,MajorClaim,2471,2542,"this regimen could not be recommended for a phase III randomized study."
11790211,Claim,1,131,"Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon."
11790211,MajorClaim,132,192,"The safety and efficacy of LAC for colon cancer are unknown,"
11790211,MajorClaim,197,311,"the nature and magnitude of any quality-of-life (QOL) benefit resulting from LAC for colon cancer is also unknown."
11790211,Premise,927,1202,"In an intention-to-treat analysis comparing SDS pain intensity, SDS summary, QOL Index summary, and global rating scale scores at each time point, the only statistically significant difference observed between groups was the global rating scale score for 2 weeks postsurgery."
11790211,Premise,1203,1337,"The mean (median) global rating scale scores for 2 weeks postsurgery were 76.9 (80) for LAC vs 74.4 (75) for open colectomy (P =.009)."
11790211,Premise,1338,1604,"While in the hospital, patients assigned to LAC required fewer days of both parenteral analgesics compared with patients assigned to open colectomy (mean [median], 3.2 [3] vs 4.0 [4] days; P<.001) and oral analgesics (mean [median], 1.9 [1] vs 2.2 [2] days; P =.03)."
11790211,Claim,1605,1717,"Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy."
11790211,Claim,1718,1913,"Until ongoing trials establish that LAC is as effective as open colectomy in preventing recurrence and death from colon cancer, this procedure should not be offered to patients with colon cancer."
11821453,Premise,391,520,"The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses."
11821453,Premise,521,707,"Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively."
11821453,Premise,708,823,"The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively."
11821453,Premise,824,1044,"The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively."
11821453,Premise,1045,1228,"Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later."
11821453,Premise,1229,1367,"The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%)."
11821453,Premise,1368,1538,"Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab."
11821453,Claim,1539,1641,"There was no clear evidence of a dose-response relationship for response, survival, or adverse events."
11821453,Claim,1642,1824,"Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH."
11830607,Claim,1,107,"Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy."
11830607,Premise,811,957,"Older patients had a higher incidence of cardiovascular (P =.009) and respiratory (P =.04) comorbidities and nonanalgesic medication use (P =.02)."
11830607,Premise,958,1070,"Leukopenia (P<.001) and neuropsychiatric toxicity (P =.002) were more common in elderly men than in younger men."
11830607,Premise,1071,1131,"Elderly women lost more weight than younger women (P =.006)."
11830607,Premise,1196,1618,"The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P =.66), median time to progression (4.37 versus 4.30 months; log-rank test, P =.29), and survival distribution (log-rank test, P =.29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older."
11830607,Premise,1619,1687,"Baseline quality-of-life and treatment-outcome indices were similar."
11830607,Premise,1688,1767,"Equivalent declines over time in functional well-being occurred in both groups."
11830607,Claim,2049,2116,"Advanced age alone should not preclude appropriate NSCLC treatment."
11830607,Claim,1768,1922,"Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients,"
11830607,Claim,1923,2048,"although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity."
11830607,Premise,1132,1195,"Other toxic effects were similar in older and younger patients."
11843249,Premise,1061,1298,"The partial and complete response rate (PR + CR) was significantly greater for patients receiving SIR-Spheres when measured by tumor areas (44%) vs. 17.6%, P = 0.01) tumor volumes (50% vs. 24%, P = 0.03) and CEA (72% vs. 47%, P = 0.004)."
11843249,Premise,1299,1611,"The median time to disease progression in the liver was significantly longer for patients receiving SIR-Spheres in comparison to patients receiving HAC alone when measured by either tumor areas (9.7 vs. 15.9 months, P = 0.001), tumor volumes (7.6 vs. 12.0 months, P = 0.04) or CEA (5.7 vs. 6.7 months, P = 0.06)."
11843249,Premise,1612,1766,"The one, two, three and five-year survival for patients receiving SIR-Spheres was 72%, 39%, 17% and 3.5%, compared to 68%, 29%, 6.5% and 0% for HAC alone."
11843249,Premise,1767,1908,"Cox regression analysis suggests an improvement in survival for patients treated with SIR-Spheres who survive more than 15 months (P = 0.06)."
11843249,Premise,1909,2083,"There was no increase in grade 3-4 treatment related toxicity and no loss of quality of life for patients receiving SIR-Spheres in comparison to patients receiving HAC alone."
11843249,Claim,2084,2273,"The combination of a single injection of SIR-Spheres plus HAC is substantially more effective in increasing tumor responses and progression free survival than the same regimen of HAC alone."
11896110,Claim,1,278,"Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS)."
11896110,Claim,279,388,"Treatment with high-dose IL-2 can cause severe toxicity and is normally administered in an inpatient setting."
11896110,Premise,902,1018,"At a median follow-up of 18 (CT) and 16 (bioCT) months, median OS was 9.5 versus 11.0 months (P =.51), respectively."
11896110,Premise,1019,1189,"In the 89 CT-arm patients, 18 ORs (20.2%) (three complete responders [CRs] and 15 partial responders [PRs]) were observed according to World Health Organization criteria."
11896110,Premise,1190,1281,"In the 87 bioCT-arm patients, 22 ORs (25.3%) (three CRs and 19 PRs) (P =.70) were recorded."
11896110,Premise,1282,1341,"Treatment-related toxicity was fairly similar in both arms."
11896110,Claim,1342,1469,"The addition of low-dose immunotherapy did not produce a statistically significant advantage in OS, time to progression, or OR."
11896110,Claim,1470,1632,"However, the 11-month median OS in the bioCT arm does not differ greatly from the best results with high-dose IL-2-containing regimens reported in the literature."
11896110,Claim,1646,1740,"our treatment schedule was carried out on outpatients and had an acceptable level of toxicity."
16476840,Premise,1008,1226,"Differences in mean QOL change scores from baseline to study end for epoetin alfa versus BSC were 3.17 points for the FACT-General Total, 9.90 for the FACT-An Fatigue subscale, and 7.30 for the FACT-An Anemia subscale."
16476840,Premise,1227,1440,"This was equivalent to corrections in QOL deficits attributable to epoetin alfa of 97.3%, 40.7%, and 38.0% for the FACT-General Total, FACT-An Fatigue, and FACT-An Anemia subscale scores, respectively, versus BSC."
16476840,Premise,1441,1599,"A somewhat greater QOL benefit was observed for the FACT-An Fatigue and FACT-An Anemia subscales in the subset of patients with baseline Hb levels >10.5 g/dl."
16476840,Premise,1600,1671,"Patients in this study had impaired QOL compared with population norms."
16476840,Claim,1672,1876,"Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl."
16476841,Premise,731,856,"Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions."
16476841,Premise,857,996,"EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC."
16476841,Premise,997,1356,"For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC."
16476841,Premise,1357,1396,"QOL declined in patients receiving BSC,"
16476841,Premise,1401,1536,"the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group."
16476841,Claim,1537,1739,"In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL."
16476841,Claim,1740,1847,"This study supports the positive effects of early intervention when analyzed according to initial Hb value."
16483488,Premise,813,1006,"The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively."
16483488,Premise,1007,1137,"Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017)."
16483488,Premise,1138,1265,"However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037)."
16483488,Premise,1266,1353,"There was no statistically difference between the two groups regarding quality of life."
16483488,Claim,1354,1460,"Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC."
16487438,MajorClaim,1,83,"The impact of prolonged subclinical hyperthyroidism on quality of life is unclear."
16487438,Premise,1322,1433,"After 6 months, none of the quality of life parameters in the low-TSH group was different from baseline values."
16487438,Premise,1434,1543,"In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index-20, P = 0.003),"
16487438,Premise,1544,1620,"although this parameter did not differ from the reference group at baseline."
16487438,Premise,1621,1735,"A probable worsening in role limitations as a result of physical problems (Short Form-36; P = 0.050) was observed."
16487438,Premise,1736,1781,"No improvement in the SDQ score was observed."
16487438,Claim,1782,1897,"In summary, quality of life in patients with DTC and long-term subclinical hyperthyroidism in general is preserved."
16487438,Claim,1898,1969,"Restoration of euthyroidism in general does not affect quality of life."
17664467,MajorClaim,1,143,"For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing clinical benefit with improved palliation is highly desirable."
17664467,Premise,1092,1261,"DCF significantly prolonged time to definitive worsening of KPS compared with CF (median, 6.1 v 4.8 months; hazard ratio, 1.38; 95% CI, 1.08 to 1.76; log-rank P = .009)."
17664467,Premise,1262,1359,"Although time to definitive weight loss and time to definitive worsening of appetite favored DCF,"
17664467,Premise,1408,1495,"Pain-free survival and time to first cancer pain-related opioid intake were comparable."
17664467,Claim,1663,1830,"The addition of D to CF not only significantly improved clinical benefit but also improved quality of life, time to progression, and overall survival compared with CF."
17664467,Premise,1360,1407,"the results were not statistically significant."
19704057,Premise,1257,1363,"The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor."
19704057,Premise,1364,1455,"Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively."
19704057,Premise,1456,1516,"The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18)."
19704057,Claim,1517,1677,"Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs."
19704057,Premise,1678,1763,"Because of the low number of observed deaths, survival analysis was not confirmatory."
19704057,Premise,873,1045,"Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR] = 0.34; 95% CI, 0.20 to 0.59; P = .000072)."
19704057,Premise,1046,1195,"After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group."
20006921,Premise,1109,1201,"The most commonly reported adverse events were nausea, abdominal pain, vomiting and fatigue."
20006921,Premise,1202,1319,"At the end of the study, 62.5%, 25% and 60% had stable disease in the 120 mg, 240 mg and placebo group, respectively."
20006921,Premise,1320,1397,"A higher proportion of patients in Z-360 groups reported improvement in pain."
20006921,Claim,1398,1462,"Z-360 is safe and well tolerated when combined with gemcitabine."
20009826,Premise,1019,1099,"Results were correlated with previously reported objective sensibility outcomes."
20009826,Premise,1390,1582,"There was a statistically significant improvement in all three measures in patients who were randomized to receive innervated free TRAM flaps compared with those receiving noninnervated flaps."
20009826,Claim,1583,1768,"This study demonstrates that innervation of free TRAM flaps used for breast reconstruction not only improves sensibility but also has a positive effect on patient-rated quality of life."
20026818,Premise,923,1011,"Approximately one-half had hematologic toxicities and toxicity-related treatment delays."
20026818,Premise,1012,1261,"Approximately one-quarter had neurotoxicities and/or ototoxicites, moist desquamation, pneumonia, nausea and vomiting requiring hospitalization or intravenous fluids, dehydration or malnutrition requiring hospitalization, and mild or moderate fever."
20026818,Premise,1262,1437,"Although patients receiving the current intensity-modulated radiation therapy (IMRT) protocol using the Pinnacle(3) planning system had more toxicity-related treatment delays,"
20026818,Premise,1438,1680,"they had fewer toxicities and better functional and health-related quality of life outcomes compared with those receiving conventional lateral opposing-field radiation or the initial IMRT protocol using the Best nomos PEACOCK planning system."
20026818,Claim,1681,1884,"Patients receiving CRT experience a substantial number of treatment-related adverse events, primarily affecting oropharyngeal and laryngeal function, with improvement noted for the current IMRT protocol."
20227168,Premise,1110,1237,"After 1 mo, 44.1% (26 of 59) of patients were continent in group A, while 20.3% (12 of 59) were continent in group B (p=0.018)."
20227168,Premise,1238,1356,"At 3 mo, 59.3% (35 of 59) and 37.3% (22 of 59) patients were continent in group A and group B, respectively (p=0.028)."
20227168,Premise,1357,1512,"The ICS male SF mean score showed better results in group A than in group B patients at both 1 mo (14.6 vs 18.3) and 3 mo (8.1 vs 12.2) after RP (p=0.002)."
20227168,Premise,1513,1734,"In age-adjusted logistic regression analyses, patients who performed preoperative PFME had a 0.41-fold lower risk of being incontinent 1 mo after RP and a 0.38-fold lower risk of being incontinent 3 mo after RP (p≤0.001)."
20227168,Claim,1735,1808,"Preoperative PFME may improve early continence and QoL outcomes after RP."
20227168,Claim,1809,1863,"Further studies are needed to corroborate our results."
20339140,Premise,1204,1357,"After a median follow-up time of 9.64 months, incidence rates of grades 2-4 acute diarrhea were similar in both groups (49% placebo vs 44% LAO; P = .21)."
20339140,Premise,1358,1532,"No statistically significant treatment differences in chemotherapy or radiation delivery, medical resource utilization, patient-reported bowel function, or QoL were observed."
20339140,Claim,1533,1709,"In this study, the prophylactic use of LAO did not prevent the incidence or reduce the severity of diarrhea and had no notable impact on patient-reported bowel function or QoL."
20351334,Premise,668,743,"Median PFS was 2.3 months for each arm (HR, 1.004; 95% CI, 0.841 to 1.199)."
20351334,Premise,744,891,"ORR, stable disease, median OS, were 4.4% versus 5.5%, 36.0% versus 39.6%, 6.7 versus 7.2 months (HR, 0.973; 95% CI, 0.805 to 1.176), respectively."
20351334,Premise,892,992,"No significant difference in patient benefit and QOL (Functional Assessment of Cancer Therapy-Lung)."
20351334,Premise,993,1036,"No unexpected adverse events were observed."
20351334,Premise,1037,1614,"Grade higher than 0 (vinflunine v docetaxel) anemia (82.1% v 79.8%), neutropenia (49.3 v 39.02%), thrombocytopenia (30.6% v 14.3%), febrile neutropenia (3.3% v 4.7%), constipation (39.2% v 11.7%), fatigue (36.6% v 33.9%), injection site reaction (31.9% v 0.7%), nausea (26.7% v 23.7%), vomiting (23.8% v 14.2%), alopecia (19.8% v 35.4%), stomatis (19.4% v 12.4%), abdominal pain (20.1% v 3.6%), myalgia (14.7% v 6.6%), peripheral neuropathy (10.7% v 15.0%), arthralgia (7.0% v 7.7%), diarrhea (6.2% v 12.4%), edema (1.5% v 5.4%), and nail disorders (1.1% v 5;1%) were observed."
20351334,Claim,1615,1715,"This noninferiority phase III study showed similar efficacy end points for vinflunine and docetaxel."
20351334,Claim,1716,1808,"Despite higher rates of some adverse effects (anemia, abdominal pain, constipation, fatigue)"
20351334,Claim,1809,1867,"the overall toxicity profile of vinflunine was manageable."
20351334,MajorClaim,1879,1966,"VFL may be another option in the second-line treatment of patients with advanced NSCLC."
20362386,Premise,1356,1648,"For intervention and control groups respectively, mean catheter duration was 11.74 d and 12.74 d (p=0.451); leakage on cystogram was present in six and eight cases (p=0.28); and incontinence (any involuntary urine loss) at 3 mo was 75% and 69% (p=0.391) and at 6 mo was 51% and 43% (p=0.686)."
20362386,Premise,1649,1709,"Urinary retention occurred only in one case (control group)."
20362386,Premise,1710,1836,"The percentage of cases returning to baseline in all QoL domains (except insomnia) was similar at 6 mo between the two groups."
20362386,Premise,1837,2006,"Short follow-up, lack of blinding, and probable small differences in our method of MFRR performed compared with other studies were identified as significant limitations."
20362386,Premise,2007,2086,"No significant difference in any of the analysed outcome measures was observed."
20362386,Claim,2087,2207,"Posterior reconstruction of the musculofascial complex does not appear to improve early urinary incontinence after RALP."
21296449,Premise,1687,1727,"There was no difference in OS (p=0.992)."
21296449,Premise,1565,1686,"There was a significant decrease in pain scores from baseline to post cycles 2 and 3 (p=0.025 and p=0.002, respectively)."
21296449,Premise,1365,1496,"No difference was observed in hospitalization rate, blood transfusions, antibiotics administration and non-haematological toxicity."
21296449,Premise,1041,1245,"There was no statistical difference in the number of cycles administered (arms A, B and D: median 2 cycles and arm C: median 3 cycles) and no difference in RR: arm A=6%, arm B=6%, arm C=10%, and arm D=0%."
21296449,Premise,1246,1364,"There was no statistically significant difference in grade 3/4 neutropenia and thrombocytopenia between the four arms."
21296449,Premise,1728,1857,"Median survival and 6-month survival were 61, 86, 88 and 97 days and 29%, 33%, 21% and 26% for arms A, B, C, and D, respectively."
21296449,Claim,1858,1921,"Clinical efficacy of docetaxel was observed at all dose levels."
21296449,Claim,1922,2035,"Higher dose levels were not associated with increased toxicities, use of IV antibiotics or hospitalization rates."
21296449,Premise,2045,2204,"the median survival observed is shorter than historical data and do not support further evaluation of these doses of single agent docetaxel in this population."
21366974,Premise,1867,2024,"RT was then associated with increased breast symptoms and with greater (self-reported) fatigue, but with lower levels of insomnia and endocrine side effects."
21366974,Premise,2025,2285,"These statistically significant differences in breast symptoms persisted for up to 5 years after RT [mean difference, RT was 5.27 units greater than no RT, 95% confidence interval (CI) of 1.46 to 9.07], with similar, though non-significant, trends in insomnia."
21366974,Premise,2286,2466,"No significant difference was found in the overall quality of life measure, with the no RT group having 0.36 units greater quality of life than the RT group (95% CI -5.09 to 5.81)."
21366974,Claim,2467,2603,"Breast RT is tolerated well by most older breast cancer patients without impairing their overall health-related quality of life (HRQoL)."
21366974,Claim,2683,2764,"our results show that the addition of RT does not impair overall quality of life."
21366974,Claim,2765,2861,"Further economic modelling on the longer-term costs and consequences of omitting RT is required."
22011650,Premise,729,1320,"Significantly more patients recorded improvements in HRQoL and symptoms with gefitinib in the EGFR mutation-positive subgroup (n = 259; FACT-L 70.2% versus 44.5%; odds ratio, 3.01 [95% confidence interval, 1.79-5.07]; p < 0.001; TOI 70.2% versus 38.3%; 3.96 [2.33-6.71]; p < 0.001; LCS 75.6% versus 53.9%; 2.70 [1.58-4.62]; p < 0.001), and with carboplatin/paclitaxel in the EGFR mutation-negative subgroup (n = 169; FACT-L 14.6% versus 36.3%; odds ratio, 0.31 [0.15-0.65]; p = 0.002; TOI 12.4% versus 28.8%; 0.35 [0.16-0.79]; p = 0.011; LCS 20.2% versus 47.5%; 0.28 [0.14-0.55]; p < 0.001)."
22011650,Premise,1321,1611,"Median time-to-worsening (months) FACT-L score was longer with gefitinib versus carboplatin/paclitaxel for the overall population (8.3 versus 2.5) and EGFR mutation-positive subgroup (15.6 versus 3.0), and similar for both treatments in the EGFR mutation-negative subgroup (1.4 versus 1.4)."
22011650,Premise,1612,1725,"Median time-to-improvement with gefitinib was 8 days in patients with EGFR mutation-positive tumors who improved."
22011650,Claim,1726,1945,"HRQoL and symptom endpoints were consistent with efficacy outcomes in IPASS and favored gefitinib in patients with EGFR mutation-positive tumors and carboplatin/paclitaxel in patients with EGFR mutation-negative tumors."
22097195,Premise,1297,1455,"The TTP in the test group was prolonged for 23 days when compared with that of the control group, with insignificant difference (87 days vs 64 days, P=0.063)."
22097195,Premise,1460,1592,"The scores of domains in EORTC QLQ-LC43 were statistically significantly better in the test group than in the control group (P<0.05)"
22097195,Claim,1687,1818,"The CM comprehensive regimen as MT had equivalent efficacy on TTP when compared with single-agent maintenance chemotherapy regimen."
22097195,Claim,1867,2033,"It is necessary to enlarge the sample size to further confirm the therapeutic efficacy of CM comprehensive regimen as MT in treatment of patients with advanced NSCLC."
22097195,Premise,1593,1682,"except cognitive and social functions, the symptoms of dysphagia and pain in other parts."
22097195,Claim,1819,1862,"It was advantageous over improving the QOL."
22842422,Premise,1158,1285,"Of the patients in the one-stage group, 70 percent had revision surgery, mostly because of upper pole fullness and poor ptosis."
22842422,Premise,1421,1467,"Quality of life was similar in the two groups."
22842422,Claim,1468,1544,"The permanent expander method failed significantly as a one-stage procedure."
22842422,Claim,1545,1642,"The crescent two-stage method gave the most acceptable results both objectively and subjectively."
22857983,Premise,905,1025,"Significant differences in QoL emerged in activity limitation, physical capacity, and sexual functioning, favouring IAD."
22857983,Premise,1026,1319,"No significant differences emerged in the prevalence of AEs: 87 patients in the IAD arm (31.8%) and 95 in the CAD arm (33.9%) had cardiovascular (CV) AEs (p=0.59), with 25 (9.1%) and 29 (10.4%) withdrawn (p=0.62), and 21 (7.7%) and 24 (8.6%) dying because of a CV event (p=0.70), respectively;"
22857983,Premise,1320,1403,"bone fractures occurred in 19 (6.9%) and 15 (5.4%) patients (p=0.44), respectively."
22857983,Premise,1404,1483,"Hot flushes or night sweats were the most common ADRs (47.1% vs 50.4%; p=0.44)."
22857983,Premise,1484,1602,"Erectile dysfunction (15.7% vs 7.9%; p=0.042) and depressed mood (2.2 vs 0%; p=0.032) were more common in the IAD arm."
22857983,Claim,1603,1676,"IAD showed benefits in the treatment of advanced PCa with respect to QoL."
22857983,Claim,1677,1736,"The prevalence of AEs was not significantly lower with IAD."
22868247,Premise,1098,1180,"There was no difference in overall or cancer-specific survival between the 2 arms."
22868247,Premise,1181,1276,"There was no statistically significant difference in QOL between the 2 arms at 0 and 12 months."
22868247,Premise,1277,1434,"The total mean costs at 24 months were significantly lower in the intermittent arm ($3135 vs. $8253 Canadian dollars, P=0.0167) compared with the continuous."
22868247,Premise,1435,1494,"The main limitation of this study is the small sample size."
22868247,Claim,1495,1722,"We have observed that intermittent ADT in patients with CRPCa, using a testosterone of >1.75 ngmol/L as a trigger to reinitiate LHRHa, results in a substantial cost savings with no negative impact on oncologic and QOL outcomes."
22877848,Premise,1219,1588,"In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (8·3 months [95% CI 7·1-9·5; n=93] vs 6·0 months [95% CI 5·1-6·8; n=100], hazard ratio [HR] 0·70; 95% CI 0·52-0·93, p=0·01), but not with hypofractionated radiotherapy (7·5 months [6·5-8·6; n=98], HR 0·85 [0·64-1·12], p=0·24)."
22877848,Premise,1589,1798,"For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (8·4 months [7·3-9·4; n=119] vs 7·4 months [6·4-8·4; n=123]; HR 0·82, 95% CI 0·63-1·06; p=0·12)."
22877848,Premise,1799,2093,"For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 0·35 [0·21-0·56], p<0·0001; HR for hypofractionated vs standard radiotherapy 0·59 [95% CI 0·37-0·93], p=0·02)."
22877848,Premise,2094,2493,"Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (9·7 months [95% CI 8·0-11·4] vs 6·8 months [5·9-7·7]; HR 0·56 [95% CI 0·34-0·93], p=0·02), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 0·97 [95% CI 0·69-1·38]; p=0·81)."
22877848,Premise,2507,2626,"the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18)."
22877848,Premise,2627,2705,"Grade 3-5 infections in all randomisation groups were reported in 18 patients."
22877848,Premise,2706,2946,"Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed."
22877848,Claim,2947,3047,"Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years."
22877848,Claim,3048,3189,"Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma."
22877848,Claim,3190,3289,"MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide."
22945882,Premise,847,967,"Pain reduction was significant from day 4 till end of treatment with SAMITAL® and from days 7 to 21 in placebo patients."
22945882,Premise,776,846,"No significant improvement was observed in the placebo group (n = 10)."
22945882,Premise,604,775,"Mean scores for the severity of OM were significantly (p < 0.05 versus baseline) reduced from day 31 until the end of treatment in patients treated with SAMITAL® (n = 20)."
22945882,Premise,968,1127,"SAMITAL® also significantly improved quality of life, as shown by improvements in scores for relevant daily activities including eating, drinking and sleeping."
22945882,Premise,1229,1355,"No severe adverse events were observed with SAMITAL®, and systemic absorption of relevant active ingredients was undetectable."
22945882,Claim,1356,1515,"SAMITAL® significantly decreased the severity of chemo/radiotherapy-induced OM in patients with head and neck cancer, with no treatment-related adverse events."
22945882,Claim,1516,1705,"Pain relief lasted through the treatment period, and improvements in quality of life were reflected by the significant benefits of SAMITAL® on activities like drinking, eating and speaking."
23017512,Premise,698,888,"At 0, 3, 6 and 12 months mean urine loss in the control vs the bladder neck preservation group was 713.3 vs 237.0, 49.6 vs 15.6, 44.4 vs 5.5 and 25.4 vs 3.1 gm, respectively (each p <0.001)."
23017512,Premise,889,1195,"At 3, 6 and 12 months in the control vs the preservation group the social continence rate was 55.3% vs 84.2% (p <0.001), 74.8% vs 89.5% (p = 0.05) and 81.4% vs 94.7% (p = 0.027), and the quality of life score was 80.4 vs 90.3 (p <0.001), 85.4 vs 91.7 (p = 0.016) and 86.0 vs 93.8 (p = 0.001), respectively."
23017512,Premise,1196,1380,"We noted significantly less urine loss, higher objective and social continence rates, and higher quality of life scores after complete bladder neck preservation at all followup points."
23017512,Premise,1510,1656,"No significant difference was found in surgical margin status between the control and bladder neck preservation groups (12.5% vs 14.7%, p = 0.65)."
23017512,Claim,1657,1956,"In what is to our knowledge the first prospective, randomized, controlled, single blind trial complete bladder neck preservation during radical prostatectomy was associated with a significantly higher urinary continence rate and increased patient satisfaction without compromising resection margins."
23294853,Premise,1432,1634,"The 2-weekly administration was associated with significantly longer TTTF than was 3-weekly administration (5·6 months, 95% CI 5·0-6·2 vs 4·9 months, 4·5-5·4; hazard ratio 1·3, 95% CI 1·1-1·6, p=0·014)."
23294853,Premise,1635,1872,"Grade 3-4 adverse events occurred more frequently in the 3-weekly than in the 2-weekly administration group, including neutropenia (93 [53%] vs 61 [36%]), leucopenia (51 [29%] vs 22 [13%]), and febrile neutropenia (25 [14%] vs six [4%])."
23294853,Premise,1873,2006,"Neutropenic infections were reported more frequently in patients who received docetaxel every 3 weeks (43 [24%] vs 11 [6%], p=0·002)."
23294853,Claim,2007,2237,"Administration of docetaxel every 2 weeks seems to be well tolerated in patients with castration-resistant advanced prostate cancer and could be a useful option when 3-weekly single-dose administration is unlikely to be tolerated."
23333117,Premise,1874,2024,"Overall, the mean global QoL score improved during chemotherapy by 7·2 points (SD 24·4) when analysed for all women with data at baseline and week 18."
23333117,Premise,2025,2227,"The mean global QoL score at 54 weeks was higher in the standard chemotherapy group than in the bevacizumab group (76·1 [SD 18·2] vs 69·7 [19·1] points; difference 6·4 points, 95% CI 3·7-9·0, p<0·0001)."
23333117,Claim,2228,2406,"Bevacizumab continuation treatment seems to be associated with a small but clinically significant decrement in QoL compared with standard treatment for women with ovarian cancer."
23352440,Premise,1107,1237,"Intervention increased SF36 score by 9.5 points (p=0.000006), 4.6 (p=0.032) and 6.2 (p=0.028) respectively at 6, 12 and 24 months."
23352440,Premise,1238,1318,"Effect size (ES) was 0.63 [0.37; 0.90], 0.29 [0.03; 0.55] and 0.41 [0.04; 0.78]."
23352440,Premise,1319,1531,"Anxiety score was shortly minored by intervention (6-month ES=-0.24 [-0.42; -0.05]) and depression score more durably: ES=-0.45 [-0.72; -0.18], -0.34 [-061; -0.08], and -0.26 [-0.63; 0.11] at 6, 12 and 24 months."
23352440,Claim,1532,1645,"This 2-week group intervention seemed to durably influence QoL of breast cancer patients treated by chemotherapy."
23352440,Claim,1646,1781,"Differences, smaller at 12 months than at six, suggest that a second but shorter intervention could help maintain the 6-month benefits."
23404211,Premise,755,892,"Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41-0.94)."
23404211,Premise,893,987,"Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33-0.50)."
23404211,Premise,988,1149,"Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients."
23404211,Premise,1150,1328,"The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients."
23404211,Premise,1329,1408,"Grade 1/2 interstitial lung disease occurred more frequently in Asian patients."
23404211,Premise,1409,1478,"Quality of life was similar between treatment arms in Asian patients."
23404211,Claim,1479,1601,"Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles."
23404211,Claim,1602,1803,"This combination represents an improvement in the management of postmenopausal women with HR(+)/HER2(-) advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity."
23545101,Premise,1308,1352,"Treatment was well tolerated in both groups,"
23545101,Premise,1353,1460,"although local and systemic side effects were more frequently reported in the bacillus Calmette-Guérin arm."
23545101,Premise,1461,1572,"Multivariate analyses showed no significant differences between the 2 groups in all quality of life dimensions."
23545101,Premise,1573,1794,"No significant changes over time in quality of life domains were detected for patients on bacillus Calmette-Guérin and gemcitabine except for physical functioning, which decreased significantly in both groups (p = 0.002)."
23545101,Premise,1795,1915,"No significant differences were detected in terms of recurrence and progression between the 2 groups at 1-year followup."
23545101,Claim,1922,2054,"a higher rate of side effects, albeit mild to moderate, was detected with 1/3 dose bacillus Calmette-Guérin compared to gemcitabine,"
23545101,Claim,2055,2152,"our study failed to show significant differences between the 2 drugs in terms of quality of life."
23545101,MajorClaim,1,146,"Bacillus Calmette-Guérin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer."
23657969,Claim,1550,1828,"This randomized controlled trial revealed that TSM program appears to be a feasible and acceptable intervention and may be associated with short-term improvements in objective and subjective cognitive function as well as mental health and spirituality in breast cancer patients."
23657969,Premise,1134,1549,"Relative to the control group, women in the TSM group performed better on the verbal memory test (Rey Auditory Verbal Learning Test trial 1) (p = 0.06) and the short-term memory and processing speed task (Digit Symbol) (p = 0.09) and reported improved cognitive function (p = 0.06), cognitive abilities (p = 0.08), mental health (p = 0.04), and spirituality (p = 0.05) at the end of treatment but not 1 month later."
23686277,Premise,1058,1138,"The trial had to be stopped prematurely due to insufficient patient recruitment."
23686277,Premise,1139,1255,"There was no difference in the amount of blood loss between both groups: LAP 261.5 ± 195.4 ml, CON 228.1 ± 119.5 ml."
23686277,Claim,1299,1371,"Laparoscopic surgery was superior regarding the length of skin incision;"
23686277,Claim,1385,1449,"the conventional approach was superior in duration of operation."
23686277,Premise,1450,1586,"There were no discrepancies in length of hospital stay, postoperative pain, bowel function, and quality of life between both approaches."
23686277,Claim,1644,1729,"There was no difference with respect to blood loss between the LAP and the CON group."
23686277,Claim,1730,1839,"The LAP approach is feasible for restorative proctocolectomy, and IPAA seems at least as safe as CON surgery."
23690410,Premise,1094,1343,"At 12 months, significant intervention effects were observed for moderate physical activity (28.5 minutes; P = .003), body mass index (-0.9 kg/m(2); P = .001), energy from total fat (-7.0%; P = .006), and energy from saturated fat (-2.8%; P = .016)."
23690410,Premise,1344,1457,"A significant intervention effect was reported for vegetable intake (0.4 servings per day; P = .001) at 6 months."
23690410,Premise,1458,1599,"No significant group differences were found at 6 or 12 months for HRQoL, cancer-related fatigue, fruit, fiber, or alcohol intake, or smoking."
23690410,Claim,1600,1741,"The CanChange intervention was effective for improving physical activity, dietary habits, and body mass index in colorectal cancer survivors."
23696477,Premise,913,1057,"Median MFD time was reduced in the ERP group (3 days versus 6 days with standard care; P < 0·001), as was LOS (4 days versus 7 days; P < 0·001)."
23696477,Premise,1058,1156,"The ERP significantly reduced the rate of medical complications (7 versus 27 per cent; P = 0·020),"
23696477,Premise,1157,1312,"but not surgical complications (15 versus 11 per cent; P = 0·612), readmissions (4 versus 0 per cent; P = 0·153) or mortality (both 2 per cent; P = 0·987)."
23696477,Premise,1313,1384,"QoL over 28 days was significantly better in the ERP group (P = 0·002)."
23696477,Premise,1385,1433,"There was no difference in patient satisfaction."
23696477,Claim,1434,1495,"ERPs for open liver resection surgery are safe and effective."
23696477,Claim,1496,1627,"Patients treated in the ERP recovered faster, were discharged sooner, and had fewer medical-related complications and improved QoL."
24045440,Claim,1901,1942,"Fecal incontinence seems to be a problem."
24045440,Claim,1668,1721,"The outcome of these patients remains unsatisfactory."
24045440,Premise,1722,1900,"Prognostic factors for a favorable outcome are tumor size of smaller than 5 cm, negative locoregional lymph nodes, age less than 10 years, low IRS group, and embryonal histology."
24045440,Premise,1534,1667,"The median Wexner fecal incontinence score was 9 (possible range: 0-20), and the median QOL score was 90.5 (applicable range: 0-144)."
24045440,Premise,1479,1533,"Some patients reported symptoms of fecal incontinence."
24045440,Premise,1341,1478,"Patients with embryonal histology had a significantly better 5-year EFS (87.5%) than patients with alveolar histology (39.1%; P = 0.013)."
24084921,Premise,1059,1305,"During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53)."
24084921,Premise,1306,1524,"Other risks included increased stroke, pulmonary embolism, dementia (in women aged ≥65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms."
24084921,Premise,1525,1577,"Most risks and benefits dissipated postintervention,"
24084921,Premise,1578,1740,"although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48])."
24084921,Premise,1741,2107,"The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97)."
24084921,Premise,2211,2390,"For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P < .05 for trend by age)."
24084921,Premise,2391,2699,"Absolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years."
24084921,Claim,2759,2830,"Menopausal hormone therapy has a complex pattern of risks and benefits."
24084921,Claim,2831,3004,"Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention,"
24084921,Claim,3005,3069,"although it is appropriate for symptom management in some women."
24092240,Premise,1045,1176,"CM five-element music group showed a significant difference of HQOLI-R, KPS and symptom diary score with other groups (all P<0.01)."
24092240,Premise,1177,1353,"There were significant differences of HQOLI-R, symptom diary score, and KPS after treatment in CM five-element music group and other groups in the non-senior subgroup (P<0.05)."
24092240,Premise,1368,1493,"there were significant differences in HQOLI-R and KPS after treatment among the three groups in the senior subgroup (P<0.05)."
24092240,Claim,1494,1699,"CM five-element music therapy could improve the quality of life and KPS for senior and non senior advanced cancer patients, and it could improve subjective symptoms for non-senior advanced cancer patients."
24123482,Claim,1959,2056,"This may lead to reduced distress and fatigue, and consequently improved QoL of cancer survivors."
24123482,Claim,1863,1958,"In addition to physical activity, future interventions should target self-efficacy and mastery."
24123482,Claim,1670,1862,"The beneficial effect of group-based physical exercise on QoL was mediated by increased physical activity, general self-efficacy and mastery, and subsequent reductions in fatigue and distress."
24123482,Premise,1569,1669,"increased physical activity was directly associated with improved QoL (β = 3.37, 95%CI = 1.01;5.54)."
24123482,Premise,1425,1559,"Reductions in fatigue (β = -1.33, 95%CI =-1.85;-0.83) and distress (β = -0.86, 95%CI = -1.25;-0.52) were associated with improved QoL."
24123482,Premise,1196,1424,"The intervention had a borderline significant direct effect on reduced distress (β = -1.32, 95%CI = -2.68;0.11), and a significant indirect effect via increased general self-efficacy and mastery (β = -1.06, 95%CI = -1.89;-0.38)."
24123482,Premise,939,1195,"the intervention had both a direct effect on fatigue (β = -1.09, 95%CI = -2.12;0.01), and an indirect effect (β = -0.54, 95%CI = -1.00;-0.21) via physical activity (β = -0.29, 95%CI = -0.64;-0.07) and general self-efficacy (β = -0.25, 95%CI = -0.61;-0.05)."
24123482,Premise,715,929,"The intervention was associated with increased physical activity (β = 0.46, 95% confidence interval (CI) = 0.14;0.59), general self-efficacy (β = 2.41, 95%CI = 0.35;4.73), and mastery (β = 1.75, 95%CI = 0.36;2.78)."
9093725,MajorClaim,1,218,"The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality."
9093725,Premise,865,1075,"More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05)."
9093725,Premise,1076,1280,"A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01)."
9093725,Premise,1281,1358,"Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)"
9093725,Premise,1359,1428,"although the difference was not statistically significant (P = 0.12)."
9093725,Premise,1429,1579,"After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003)."
9093725,Premise,1580,1739,"Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03)."
9093725,Claim,1740,1847,"The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer."
9093725,Claim,1848,1932,"The number of patients who benefit from treatment is, however, still rather limited."
9106647,Premise,1630,1903,"Survival was inferior at 1 year in the oral etoposide group compared with intravenous therapy (9.8% for oral versus 19.3% for intravenous; difference = 9.5%; 95% confidence interval of difference = 0.3%-18.7%; P<.05), and there was a trend toward inferior overall survival."
9106647,Premise,1904,1993,"Median survival was 4.8 months for oral treatment and 5.9 months for intravenous therapy."
9106647,Premise,1994,2166,"Progression-free survival was worse in the oral etoposide arm (median = 3.6 months versus 5.6 months; P<.001), as well as overall response rate (32.9% versus 46.3%; P<.01)."
9106647,Premise,2167,2256,"With the exception of acute nausea and vomiting associated with intravenous chemotherapy,"
9106647,Claim,2398,2599,"These interim results show that this schedule of oral etoposide is inferior to intravenous chemotherapy in the treatment of advanced SCLC and should not be used as first-line treatment of this disease."
9106647,Premise,2257,2366,"all aspects of symptom control and quality of life were either the same or worse in the oral etoposide group."
9137798,Premise,747,987,"Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend."
9137798,Premise,988,1184,"A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P < or = 0.001)."
9137798,Premise,1185,1346,"Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P = 0.002)."
9137798,Premise,1347,1419,"Improvements in QoL occurred early within four weeks and were sustained."
9137798,Premise,1420,1523,"No statistically significant differences were observed in NS measurements, including weight (P = 0.29)."
9137798,Premise,1524,1610,"Side effects of therapy were minor and did not differ significantly across treatments."
9137798,Claim,1611,1725,"Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer."
9137798,Claim,1726,1799,"It improves appetite, mood and overall quality of life in these patients,"
9137798,Claim,1800,1859,"although not through a direct effect on nutritional status."
9143576,MajorClaim,1,128,"The choice of reconstruction after gastrectomy and the significance of remaining reservoir function is a matter of controversy."
9143576,Premise,894,1023,"The postoperative complication and mortality rates were similar in all treatment groups, with few serious complications recorded."
9143576,Premise,1024,1150,"Irrespective of type of treatment, the patients suffered from alimentary symptoms and functional limitations in everyday life,"
9143576,Premise,1151,1206,"whereas their mental well-being improved after surgery."
9143576,Premise,1207,1323,"Patients who underwent subtotal gastrectomy had the best outcome, especially with respect to complaints of diarrhea."
9143576,Premise,1324,1443,"Patients given a gastric substitute after gastrectomy showed no difference from those who had only a total gastrectomy."
9143576,Claim,1444,1579,"We conclude that despite significant unfavorable consequences that follow gastrectomy, patients recover with an improved mental status."
9143576,Claim,1580,1660,"A pouch reconstruction after total gastrectomy does not improve quality of life,"
9143576,Claim,1665,1769,"a subtotal gastrectomy has advantages that must be considered when the procedure is clinically feasible."
